Literature DB >> 31436802

Factors Associated With Immune Checkpoint Inhibitor-Related Myocarditis.

Yoshito Zamami1,2, Takahiro Niimura1, Naoto Okada2, Toshihiro Koyama3, Keijo Fukushima4, Yuki Izawa-Ishizawa5, Keisuke Ishizawa1,2.   

Abstract

Entities:  

Year:  2019        PMID： 31436802      PMCID： PMC6707099          DOI： 10.1001/jamaoncol.2019.3113

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN： 2374-2437            Impact factor:   31.777


× No keyword cloud information.
  23 in total

1.  Demographic Factors Associated with Toxicity in Patients Treated with Anti-Programmed Cell Death-1 Therapy.

Authors:  Kaustav P Shah; Haocan Song; Fei Ye; Javid J Moslehi; Justin M Balko; Joe-Elie Salem; Douglas B Johnson
Journal:  Cancer Immunol Res       Date:  2020-04-29       Impact factor: 11.151

Review 2.  Sex-Specific Cardiovascular Risks of Cancer and Its Therapies.

Authors:  Nicholas S Wilcox; Seth J Rotz; McKay Mullen; Evelyn J Song; Betty Ky Hamilton; Javid Moslehi; Saro H Armenian; Joseph C Wu; June-Wha Rhee; Bonnie Ky
Journal:  Circ Res       Date:  2022-02-17       Impact factor: 17.367

3.  CV complications of anti-cancer ICI therapy and their combinations: are we ready for challenges ahead?

Authors:  Alexandros Georgiou; Nadia Yousaf
Journal:  Br J Cardiol       Date:  2020-01-29

4.  Identification of Pathogenic Immune Cell Subsets Associated With Checkpoint Inhibitor-Induced Myocarditis.

Authors:  Han Zhu; Francisco X Galdos; Daniel Lee; Sarah Waliany; Yuhsin Vivian Huang; Julia Ryan; Katherine Dang; Joel W Neal; Heather A Wakelee; Sunil A Reddy; Sandy Srinivas; Lih-Ling Lin; Ronald M Witteles; Holden T Maecker; Mark M Davis; Patricia K Nguyen; Sean M Wu
Journal:  Circulation       Date:  2022-06-28       Impact factor: 39.918

5.  Case Report: Acute Myocarditis Due to PD-L1 Inhibitor Durvalumab Monotherapy in a Patient With Lung Squamous Cell Carcinoma.

Authors:  Bo Zhou; Manxiang Li; Tianjun Chen; Jianqing She
Journal:  Front Med (Lausanne)       Date:  2022-06-21

Review 6.  Exploring the Mechanisms Underlying the Cardiotoxic Effects of Immune Checkpoint Inhibitor Therapies.

Authors:  Daniel Ronen; Aseel Bsoul; Michal Lotem; Suzan Abedat; Merav Yarkoni; Offer Amir; Rabea Asleh
Journal:  Vaccines (Basel)       Date:  2022-03-31

7.  Spontaneous and Immune Checkpoint Inhibitor-Induced Autoimmune Diseases: Analysis of Temporal Information by Using the Japanese Adverse Drug Event Report Database.

Authors:  Keiko Ogawa; Yoshihiro Kozuka; Hitomi Uno; Kosuke Utsumi; Osamu Noyori; Rumiko Hosoki
Journal:  Clin Drug Investig       Date:  2021-06-10       Impact factor: 2.859

Review 8.  Endocrine toxicities of immune checkpoint inhibitors.

Authors:  Jordan J Wright; Alvin C Powers; Douglas B Johnson
Journal:  Nat Rev Endocrinol       Date:  2021-04-19       Impact factor: 43.330

9.  Durvalumab-induced myocarditis, myositis, and myasthenia gravis: a case report.

Authors:  Jason Cham; Daniel Ng; Laura Nicholson
Journal:  J Med Case Rep       Date:  2021-05-31

Review 10.  Mechanisms and clinical manifestations of cardiovascular toxicities associated with immune checkpoint inhibitors.

Authors:  Alan H Baik; Katy K Tsai; David Y Oh; Mandar A Aras
Journal:  Clin Sci (Lond)       Date:  2021-03-12       Impact factor: 6.124
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.